B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

15.20 -0.03 (-0.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,038,446
Open 15.01
Bid (Size) 14.32 (200)
Ask (Size) 15.67 (2,800)
Prev. Close 15.23
Today's Range 14.63 - 15.23
52wk Range 6.360 - 25.00
Shares Outstanding 58,310,703
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing ↗
This clinical-stage biotech develops therapies for rare muscle diseases using its proprietary FORCE platform and research-driven approach. 
Via The Motley Fool
Topics Regulatory Compliance
Dyne Therapeutics Inc (NASDAQ:DYN) Reports Narrower-Than-Expected Q4 2025 Loss, Reaffirms Key Clinical Timelines ↗
Via Chartmill

Performance

YTD
-17.8%
-17.8%
1 Month
-19.8%
-19.8%
3 Month
-26.4%
-26.4%
6 Month
+14.8%
+14.8%
1 Year
+24.8%
+24.8%

More News

Read More
News headline image
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Participate in Upcoming Investor Conferences
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday ↗
Via The Motley Fool
News headline image
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Dyne Therapeutics Stock Tanked on Tuesday ↗
Via The Motley Fool
News headline image
Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More ↗
Via The Motley Fool
Topics Artificial Intelligence Bonds Economy
News headline image
Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears
Via MarketMinute
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
Via The Motley Fool
News headline image
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
Via The Motley Fool
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
From Dyne Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
Via MarketMinute
News headline image
Why Dyne Therapeutics Stock Was Crushing it This Week ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
Via Benzinga
News headline image
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
From Dyne Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Dyne Therapeutics, Inc. - Common Stock publicly traded?
Yes, Dyne Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Dyne Therapeutics, Inc. - Common Stock trade on?
Dyne Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Dyne Therapeutics, Inc. - Common Stock?
The ticker symbol for Dyne Therapeutics, Inc. - Common Stock is DYN on the Nasdaq Stock Market
What is the current price of Dyne Therapeutics, Inc. - Common Stock?
The current price of Dyne Therapeutics, Inc. - Common Stock is 15.20
When was Dyne Therapeutics, Inc. - Common Stock last traded?
The last trade of Dyne Therapeutics, Inc. - Common Stock was at 03/05/26 04:00 PM ET
What is the market capitalization of Dyne Therapeutics, Inc. - Common Stock?
The market capitalization of Dyne Therapeutics, Inc. - Common Stock is 886.32M
How many shares of Dyne Therapeutics, Inc. - Common Stock are outstanding?
Dyne Therapeutics, Inc. - Common Stock has 886M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.